In:
Transfusion, Wiley, Vol. 54, No. 7 ( 2014-07), p. 1817-1822
Kurzfassung:
CD 59 is a cell surface glycoprotein of approximately 20 kDa limiting the lytic activity of the terminal complement complex C 5b‐9. Although CD 59 is known as a red blood cell ( RBC ) antigen defined by monoclonal antibodies, it so far has not been identified as a blood group antigen, since the description of a human alloantibody was missing. In this study we show the presence of an anti‐ CD 59 in a patient affected by a homozygous CD 59 deficiency. Study Design and Methods RBC CD 59 and CD 55 were determined by flow cytometry or by the column agglutination technique using monoclonal antisera. Commercially available His‐tagged recombinant soluble CD 59 protein was used to inhibit anti‐ CD 59. Results Seven cases of an isolated CD 59 deficiency due to three distinct null alleles of the CD 59 gene have been published so far. Recently we described the CD 59 ‐null allele c.146del A in a young child of heterozygous parents. Her plasma contained an alloantibody directed against the high‐prevalence RBC antigen CD 59. The antibody specificity was identified using soluble recombinant human CD 59 protein, which blocked the reactivity of the patient's antibody and of monoclonal anti‐ CD 59 but not of monoclonal anti‐ CD 55. In addition, RBC alloantibodies such as anti‐ K , anti‐ C , anti‐c, or anti‐ F y a remained unaffected. Therefore, inhibition by recombinant CD 59 is a useful diagnostic tool to detect alloantibodies in the presence of anti‐ CD 59. Conclusion This is the first demonstration of a human anti‐ CD 59 alloantibody, which defines CD 59 as an RBC blood group antigen. CD 59 represents a candidate for a new blood group system.
Materialart:
Online-Ressource
ISSN:
0041-1132
,
1537-2995
DOI:
10.1111/trf.2014.54.issue-7
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2014
ZDB Id:
2018415-3
